Durvalumab consolidation in patients with unresectable stage III non-small cell lung cancer with driver genomic alterations
Mariona Riudavets, Édouard Auclin, Miguel Mosteiro, Naomi Dempsey, Margarita Majem, Riccardo Lobefaro, Rafael López Castro, Joaquim Bosch‐Barrera, Sara Pilotto, E. Escalera, Marco Tagliamento, Joaquín Mosquera, Gérard Zalcman, Frank Aboubakar Nana, Santiago Ponce, Alessandro Dal Maso, Martina Spotti, Xabier Mielgo-Rubio, Elodie Mussat, Roxana Reyes, José Carlos Benítez, Lorena Lupinacci, Boris Duchemann, Andrea De Giglio, Juan Bautista Blaquier, Clarisse Audigier-Valette, Matthias Scheffler, Ernest Nadal, Gilberto Lopes, Diego Signorelli, Rosario García‐Campelo, Jessica Menis, Virginia Bluthgen, Marc Campayo, Gonzalo Recondo, Benjamin Besse, David Planchard, Laura Mezquita
Topics & Concepts
MedicineDurvalumabInternal medicineStage (stratigraphy)Lung cancerKRASOncologyRadiation therapyHazard ratioGastroenterologyAdenocarcinomaCohortRetrospective cohort studyCancerSurgeryConfidence intervalImmunotherapyColorectal cancerPaleontologyBiologyNivolumabLung Cancer Diagnosis and TreatmentLung Cancer Treatments and MutationsCancer Immunotherapy and Biomarkers